Cart is empty The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approved for treatment for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients aged 2 months or older, according to a press release from the U.S. Food and Drug Administration.
Leave A Comment